首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

【2h】

P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
S Eketorp Sylvan; J Lundin; M Ipek; M Palma; C Karlsson; L Hansson;
展开▼
作者单位

展开▼
年(卷),期 2014(2),Suppl 2
年度 2014
页码 P18
总页数 2
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients [J] . S Eketorp Sylvan, J Lundin, M Ipek, Journal for ImmunoTherapy of Cancer . 2014,第S2期

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验
2. Aleintuiumab (anti-CD52 monoclonal antibody) ms single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients [J] . S. Eketorp Sylvan, J. Lundin, M. Ipek, Annals of hematology . 2014,第10期

机译：复发性/难治性慢性淋巴细胞白血病（CLL）患者的Aleintuiumab（抗CD52单克隆抗体）ms单药治疗-连续患者的单区域经验
3. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience [J] . Thompson Philip A., Rozovski Uri, Keating Michael J., British Journal of Haematology . 2015,第2期

机译：与来那度胺单药治疗相比，向来那度胺添加CD20单克隆抗体可提高复发率/难治性慢性淋巴细胞白血病患者的应答率和生存率-MD安德森癌症中心的经验
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Experiences of Single-session Improvisational Group Music Therapy: Therapist and Patient Reflections from Inpatient Psychiatry [D] . Chen, Yu-Ying 2019

机译：单节期即兴团体音乐治疗的经验：住院精神病学的治疗师和患者的思考
6. The Addition of CD20 Monoclonal Antibodies to Lenalidomide Improves Response Rates and Survival in Relapsed/refractory patients with CLL Relative to Lenalidomide Monotherapy – The MD Anderson Cancer Center Experience [O] . Philip A. Thompson, Uri Rosovski, Michael J. Keating, -1

机译：与来那度胺单药治疗相比向来那度胺加CD20单克隆抗体可改善复发/难治性CLL复发/难治性患者的应答率和生存率– MD安德森癌症中心的经验
7. P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients [O] . S Sylvan, J Lundin, M Ipek, 2014

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验

P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

著录项

相似文献

相关主题

期刊订阅